McKinley Capital Management’s Corcept Therapeutics CORT Stock Holding History

McKinley Capital Management’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-5,798	Closed	-$81K	–	291
2018 Q3	$81K	Sell	5,798 -457	-7%	-$6.39K	0.01%	269
2018 Q2	$98K	Sell	6,255 -519	-8%	-$9.03K	0.01%	267
2018 Q1	$111K	Sell	6,774 -302,049	-98%	-$5.6M	0.01%	257
2017 Q4	$5.58M	Buy	308,823 +216	+0.1%	+$3.91K	0.28%	72
2017 Q3	$5.96M	Sell	308,607 -136,910	-31%	-$2.04M	0.24%	73
2017 Q2	$5.26M	Buy	445,517 +248,504	+126%	+$2.7M	0.2%	79
2017 Q1	$2.16M	Buy	+197,013	New	+$1.73M	0.08%	167

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

McKinley Capital Management's CORT Position: Q4 2018 in Review

McKinley Capital Management sold out of Corcept Therapeutics (CORT) in Q4 2018, closing a stake of 5,798 shares — an estimated $81K sold.

McKinley Capital Management first reported a position in CORT in Q1 2017 and held it in 7 quarters. The position peaked at $5.96M in Q3 2017. 222 funds tracked by Wall St. Rank hold CORT as of Q4 2018.

McKinley Capital Management reported no remaining Corcept Therapeutics position as of Q4 2018 after selling out during the quarter.
McKinley Capital Management sold 5,798 Corcept Therapeutics shares in Q4 2018, an estimated $81K.
McKinley Capital Management first reported a position in Corcept Therapeutics in Q1 2017 and held it in 7 quarters.
McKinley Capital Management's Corcept Therapeutics position peaked at $5.96M in Q3 2017.
222 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2018.

Based on McKinley Capital Management's 13F filing for Q4 2018, filed 11 Feb 2019.